ProCE Banner Activity

Medical Minute on Key Decisions in HIV Care: Treating HIV/HCV Coinfection

Multimedia
In this case example, learn the data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.

Released: January 19, 2022

Expiration: January 18, 2023

No longer available for credit.

Share

Faculty

Mark S. Sulkowski

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received funds for research support from AbbVie, Assembly Bio, Gilead Sciences, and Janssen and consulting fees from AbbVie, Antios, Arbutus, Assembly Bio, Gilead Sciences, ViiV, and Virion.